Loading...

SHINE Selects Rock Creek Innovations

April 24, 2018 – Janesville, WI – SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that it has chosen Rock Creek Innovations, LLC to lead design and implementation of the instrumentation and control (I&C) protection systems for its medical isotope production facility in Janesville, Wisconsin. 

TRPS and ESFAS cabinet

Photo: 3D model of the TRPS and ESFAS cabinet systems designed by Rock Creek Innovations for the SHINE medical isotope production facility.

With over 160 years of combined experience in architecting, designing, and implementing nuclear protection systems, Rock Creek Innovations is the inventor of the groundbreaking I&C protection system platform known as the Highly Integrated Protection System, or HIPS. The HIPS takes advantage of the best of both analog and digital control systems by combining the long-proven analog safety channel approach used by nuclear protection systems today with the comprehensive diagnostic and self-testing capabilities of digital logic. The HIPS platform has been approved by the U.S. NRC for use in safety-related applications in U.S. nuclear power plants. 

“Rock Creek’s creative thinking and passion for partnership are what differentiates them from the traditional nuclear industry contractor,” said Greg Piefer, founder and CEO of SHINE. “The entrepreneurial, problem-solving culture that Gregg Clarkson brings to his organization is well-aligned with our needs.” 

SHINE TRPS Close-up

Photo: Close-up of the TRPS system cabinet 3D model design for SHINE by Rock Creek Innovations.

“It’s an honor to be working with the SHINE team as they bring a reliable supply of HSA moly-99 to U.S. patients,” said Gregg Clarkson, President and owner of Rock Creek Innovations. “Rock Creek Innovations looks forward to being a critical member of the team that sees the SHINE project to realization.”

About Mo-99 

Molybdenum-99 (Mo-99) is a radioisotope that decays into the diagnostic imaging agent technetium-99m (Tc-99m). Tc-99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and bone scans to stage cancer. SHINE was founded to deploy a safe, cost-effective and environmentally friendly technology to produce medical isotopes, including Mo‑99. 

About SHINE Medical Technologies, Inc. 

Founded in 2010, SHINE is a development-stage company working toward becoming a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies, as it does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for molybdenum-99. In 2014, SHINE announced the execution of molybdenum-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated SHINE molybdenum-99 can act as a drop-in replacement for reactor-based moly-99. In 2016, SHINE received regulatory approval to construct its facility from the Nuclear Regulatory Commission and signed a moly-99 supply agreement with HTA Co., Ltd., the largest Chinese distributor of radiopharmaceuticals. Learn more at http://shinemed.com. 

2018-04-24T09:56:43+00:00